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The B cell receptor immunoglobulin (BcR IG) gene repertoires of marginal zone (MZ) 
lymphoproliferations were analyzed in order to obtain insight into their ontogenetic 
relationships. Our cohort included cases with MZ lymphomas (n=488) i.e. splenic (SMZL), 
nodal (NMZL) and extranodal (ENMZL) as well as provisional entities (n=76) according to the 
World Health Organization classification. The most striking IG gene repertoire skewing was 
observed in SMZL. However, restrictions were also identified in all other MZ lymphomas 
studied, particularly ENMZL, with significantly different IG gene distributions depending on 
the primary site of involvement. Cross-entity comparisons of the MZ IG sequence dataset 
with a large dataset of IG sequences (MZ-related or not; n=65,837) revealed four major 
clusters of cases sharing homologous (‘public’) heavy variable complementarity-determining 
region 3. These clusters included rearrangements from SMZL, ENMZL (gastric, salivary gland, 
ocular adnexa), chronic lymphocytic leukemia but also rheumatoid factors and non-
malignant spleen MZ cells. In conclusion, different MZ lymphomas display biased 
immunogenetic signatures indicating distinct antigen exposure histories. The existence of 
rare public stereotypes raises the intriguing possibility that common, pathogen-triggered, 
immune-mediated mechanisms, may result in diverse B lymphoproliferations due to 
targeting versatile progenitor B cells and/or operating in particular microenvironments. 
 









The 2016 update of the World Health Organization (WHO) Classification of tumors of the 
hematopoietic and lymphoid tissues [1] recognizes three distinct types of marginal zone 
(MZ) lymphomas: splenic marginal zone lymphoma (SMZL), nodal MZ lymphoma (NMZL), 
and extranodal MZ lymphoma (ENMZL). Provisional entities pertain to splenic B cell 
lymphoma leukemia unclassifiable [splenic diffuse red pulp lymphoma (SDRL); hairy cell 
leukemia variant (HCL-v)] and pediatric nodal marginal zone lymphoma. In addition, non-CLL 
type monoclonal B lymphocytosis potentially related to SMZL (also termed clonal 
lymphocytosis of MZ origin, CBL-MZ)[2,3] has been recognized for the first time. 
(Auto)antigenic stimulation and (micro)environmental interactions have been implicated in 
MZ lymphomagenesis. This claim is supported by the (i) pronounced skewing of the 
immunoglobulin (IG) gene repertoire of MZ lymphomas[4,5]; (ii) the strong association 
between chronic inflammation (due to infection or autoimmunity) and extranodal MZL 
lymphomas [6]; and, (iii) the increased incidence of genetic aberrations (recurrent 
translocations or gene mutations) affecting key components of B cell signaling pathways, 
further underscoring their significance in the natural history of these entities [7,8]. 
However, despite significant advances in characterizing the biological landscape of MZ 
lymphomas, questions abound regarding their immune pathogenesis and precise 
ontogenetic relationships.  
Here, we aimed to obtain insight into MZ lymphomagenesis through: (i) systematic 
characterization of the IG gene repertoires in MZ lymphomas and (ii) comparison of IG 
sequences from different MZ lymphoma subtypes, newly recognized clonal entities ( CBL-
MZ) and non-malignant entities [persistent polyclonal B-cell lymphocytosis, PPBL] for which 
a marginal zone origin is speculated, against a large IG gene sequence dataset. 
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MATERIALS AND METHODS 
 
Characterization of the studied IG gene sequence dataset 
Included in the study were 66,401 IGHV-IGHD-IGHJ gene rearrangement sequences from (i) 
patients with MZ lymphoproliferations (n=1339) obtained from both the collaborating 
institutions and public databases (ii) CLL (n=20,451) cases deposited into the IMGT/CLL-DB; 
and, (iii) a dataset of 44,611 IGHV-IGHD-IGHJ gene rearrangement sequences from the 
IMGT/LIGM-DB. 
The MZ dataset included: (i) Definite entities of MZ origin, namely SMZL, n=353 cases; 
NMZL, n=37 cases; ENMZL, n=98 cases; (ii) provisional entities of postulated MZ origin, 
including SDRL, n=16 cases; and, CBL-MZ, n=60 cases, (iii) PPBL, n=2 cases/286 sequences; 
and (iv) non malignant MZ cells isolated from 6 spleen specimens free of neoplastic cells at 
histological inspection (non-malignant MZ), obtained at surgery for non-hematologic cancer 
(n=489 sequences) (supplementary material, Supplementary materials and methods). 
IG gene repertoire analysis was performed only for rearrangement sequences from definite 
clonal entities of MZ origin. Sequences from non-clonal MZ lymphoproliferations and/or 
non-malignant splenic MZ cells were used for cross-comparison purposes and the 
identification of stereotyped sequences; repertoire findings from these latter subgroups are 
summarized in (supplementary material, Supplementary materials and methods).  The study 
was approved by local Ethics Review Committees. 
 
PCR amplification and immunoinformatic analysis of IGHV-IGHD-IGHJ gene 
rearrangements 
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PCR amplification and sequence analysis of IGHV-IGHD-IGHJ gene rearrangements was 
performed as described [9] and stereotyped rearrangements were identified through the 
use of a validated bioinformatics algorithm [9].  
In order to ensure consistency, all sequences underwent a multi-level evaluation aimed at 
(i) removing unproductive, incomplete and/or IGHV-IGHD-IGHJ gene rearrangement 
sequences with ambiguous characters and, (ii) eliminating redundancy. Rearrangements 
were classified as either unique (present only once in the investigated dataset), or 
recurrent, (belonging to the same clonal family) sharing the same IGHV/IGHD/IGHJ gene 
combinations and a VH CDR3 of identical length and identical or highly similar (≥60%) amino 
acid sequence. In the case of groups of recurrent sequences, only a single representative 




Comparisons and associations between different subgroups were performed with the use of 
descriptive statistics assessed using Chi-square or Fisher’s exact test for independence. The 
significance level for all tests was set to p<0.05. Statistical analyses were performed with 
the statistical package, SPSS version 22.0 (SPSS, Chicago, IL, USA). 
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RESULTS AND DISCUSSION 
 
Capitalizing on a large dataset of IGHV-IGHD-IGHJ gene rearrangement sequences available 
through our multi-institutional collaboration, we assessed the immunogenetic 
characteristics of MZ lymphomas and searched for stereotyped BcR IG sequences across MZ 
and MZ-related entities. 
IG gene repertoire analysis revealed restrictions in the use of particular IGHV genes in all 
examined MZ lymphomas indicating disease-biased patterns (Figure 1A). IGHV gene 
repertoire skewing was more pronounced in SMZL, where the IGHV1-2 gene was used by 
27.8% of all cases, in keeping with published studies by us and others [4]; no particular bias 
to any IGHV gene was noted amongst the HCV (+) SMZL cases of our cohort (supplementary 
material, Supplementary materials and methods). In NMZL, the most frequently expressed 
IGHV genes were IGHV4-34 and IGHV1-69 (13.5% each). Finally, in ENMZL the IGHV1-69 
gene predominated (16.3%) albeit with significantly different distribution depending on the 
primary site of involvement (34.8% in salivary ENMZL, 19.2% in gastric ENMZL, 6.1% in 
ocular adnexa ENMZL, OAMZL, p=0.008 for all comparisons) (Figure 1B). Information 
regarding Chlamydia psittaci (C. psittaci) infection status was available for 38 OAMZL [11] of 
whom 16 (42%) were positive. Even though not statistically significant the IGHV3-23 gene 
predominated amongst C. psittaci (-) cases (6/22 versus 2/16 in positive cases; p=0.27), 
whereas IGHV3-7 predominated amongst C. psittaci (+) cases (3/16 versus 1/22; p=0.15). H. 
pylori status in gastric ENMZL cases was not available due to the retrospective nature of the 
study. Overall, these findings confirm and significantly extend previous observations about 
the existence of IG gene repertoire biases in MZ lymphomas [12–14].  
Turning to somatic hypermutation (SHM) and following previously proposed definitions [4], 
IGHV-IGHD-IGHJ gene rearrangements carrying IGHV genes with no SHM (100% V-REGION  
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identity to that ot the closest germline gene, (germline identity (GI)) were assigned to a 
“truly unmutated” (TU) subgroup whereas sequences with 97% to 99.9% GI were classified 
as “borderline/minimally mutated”(BM) and those with <97% identity as “mutated” (M).  
The vast majority of MZL cases bore some impact of SHM. However, differences were 
identified between various MZ lymphoma subtypes regarding their SHM profiles. In 
particular, the proportion of TU cases ranged from 0% in ENMZL gastric cases to 12.2% in 
SMZL. Regarding the remaining cases bearing SHM, 37.3% of IGHV-IGHD-IGHJ gene 
rearrangements in SMZL were BM versus only 18.9% in NMZL and 18.3% in ENMZL (p=0.02 
and p=0.0004, respectively). Finally, only 50.4% of SMZL cases exhibited a significant SHM 
load versus 72.9% and 75.5% of NMZL and ENMZL cases (p=0.008 and p<0.0001, 
respectively) (Figure 2).   
Following established bioinformatics approaches[9], we searched for stereotyped BcR IG 
sequences i.e. IGHV-IGHD-IGHJ gene rearrangements with restricted antigen-binding site 
sequence motifs. Of the 66,401 IGHV-IGHD-IGHJ rearrangements included in the analysis, 
40,103 (60.4%) were assigned to at least one  stereotyped subset. Overall, 26,143 different 
clusters were recognized. Of these 2499 (9.5%) included IGHV-IGHD-IGHJ gene 
rearrangements from a single entity and were considered as ‘disease-specific’, whereas the 
remainder included rearrangements from different entities and were, thus, deemed 
‘public’. 
Most clusters (17,844/26,143; 68.3%) contained only two sequences; of the remaining 8299 
clusters with 3 or more members, 1653 (6.3% of all clusters) included six or more members. 
The vast majority of disease-specific clusters (2468/2499, 98.7%) concerned CLL cases, 
which is not paradoxical, considering that the incidence of BcR IG stereotypy is much higher 
in CLL versus all other B cell lymphomas thus far analyzed [15]. A much smaller proportion 
of ‘disease-specific’ clusters (31/2499, 1.2%) concerned MZ lymphomas, mostly SMZL.  
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Public clusters were mostly relatively small in size with only 4 being populated by more than 
20 members (supplementary material, Table S1). All 4 large public clusters included 
somatically hypermutated IGHV-IGHD-IGHJ gene rearrangements that derived from MZ 
lymphomas, non-malignant spleen MZ cells and other conditions. Two of 4 subsets utilized 
the IGHV1-69 gene, while the remaining 2 utilized the IGHV3-7 and IGHV4-59 gene, 
respectively (Figure 3). They included IGHV-IGHD-IGHJ gene rearrangements from various 
entities, including SMZL, ENMZL (gastric, salivary gland, ocular adnexa), CLL, hepatitis C 
virus-associated diffuse large B cell lymphoma (DLBCL), and non-malignant spleen MZ cells 
and rearrangements rheumatoid factors [with regards to the latter, recalling previous 
reports [11,12,16,17]. Notably, shared (recurrent) amino acid changes introduced by SHM 
(i.e. the same amino acid replacement at the same position) were identified in each large 
public cluster (supplementary material, Tables S2–5).  
As the story of antigen-driven lymphoma unfolds, multidisciplinary investigation will be 
paramount to the identification of the selecting agent(s) and immune processes underlying 
the development of MZ lymphomas. Our present findings highlight biased immunogenetic 
signatures for distinct MZ lymphomas that pertain to both distinctive IGHV gene repertoires 
and differential SHM imprints. Although highlighting (auto)antigen selection pressure as a 
major driver in MZ lymphomagenesis, these results also suggest that unique immune 
pathways lead to distinct MZ lymphomas. 
That said, the existence of rare public stereotypes raises the intriguing possibility that, 
occasionally, common patterns of immune stimulation triggered by distinct and/or cross-
reactive (auto)antigens may result in diverse B lymphoproliferations due to targeting 
versatile progenitor B cells and/or operating in particular microenvironments. Future 
immunogenetic and functional studies are clearly warranted for testing this hypothesis but 
also for offering answers as to how normal MZ cells, the presumed normal counterparts for 
This article is protected by copyright. All rights reserved.
  
  
several MZ lymphomas, are co-opted into pathogenic immune responses in these tumors; 
where does affinity maturation take place; and, what is the significance of various 
bystander cells, particularly T cells.  
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Figure 1.  
IGHV gene repertoire of marginal zone lymphomas. (A) Immunogenetic analysis of 
marginal zone lymphomas (MZLs) revealed IGHV gene repertoire skewing that was most 
pronounced in SMZL. (B) Relative frequency of the IGHV1-69 gene in different extranodal 
MZ lymphomas: significant differences depending on the primary site of involvement.  
Notes: (i) an asterisk is used to indicate the most frequent genes in each entity; (ii) in the 
repertoire analysis presented in this figure, every gene is represented by a unique color in 
all pie charts.  
 
Figure 2. 
Differential imprint of somatic hypermutation in marginal zone lymphomas. Most 
marginal zone lymphoma cases bore at least some imprint of somatic hypermutation, 
however different profiles were identified in distinct subtypes.  
 
Figure 3. 
Public clonotypic rearrangements. VH CDR3 amino acid alignment of the four largest public 
clusters i.e. clusters that were not disease-specific (comprising IGHV-IGHD-IGHJ gene 
rearrangements from a single entity) but rather included cases deriving from different MZ 
lymphoproliferations but also other lymphoma entities as well as healthy and autoreactive 
clones; additional relevant information is provided in supplementary material, Table S1. (A) 
cluster #3; (B) cluster #5; (C) cluster #12; (D) cluster #16. Construction of the logos was 
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performed with the use of WebLogo (http://weblogo.berkeley.edu/). Each letter represents 
a single amino acid whereas the size of the letter represents its frequency. Colors 
correspond to the physicochemical properties color code used by IMGT [18]. The numbering 
of the clusters is not indicative of their characteristics, nor does it correspond to the 
nomenclature for stereotypes CLL subsets, but only concerns their succession in cluster 
identification.  
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Table S1. Only four public clusters were populated with more than 20 sequences. 
These included IGHV-IGHD-IGHJ gene rearrangements of different origin such as MZ 
lymphomas, non-malignant spleen tissue and various other conditions, especially HCV-
associated entities and autoimmune disorders. Minor public clusters (populated with 
less than 10 sequences) were also identified. 
 
Table S2. Recurrent amino acid changes introduced by SHM in cluster #3 
 
Table S3. Recurrent amino acid changes introduced by SHM in cluster #5 
 
Table S4. Recurrent amino acid changes introduced by SHM in cluster #12 
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Table S5. Recurrent amino acid changes introduced by SHM in cluster #16 
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